公开(公告)号：WO2008152422A3

公开(公告)日：2009-03-12

申请号：PCT/GB2008050436

申请日：2008-06-11

Applicant: ASTRAZENECA AB ,  ASTRAZENECA UK LTD ,  BEDIAN VAHE ,  CARTLIDGE SUSAN ANN ,  GAZIT-BORNSTEIN GADI ,  RAEBER OLIVIA ,  TONGE DAVID WILLIAM ,  YANG XIAO-DONG

Inventor： BEDIAN VAHE ,  CARTLIDGE SUSAN ANN ,  GAZIT-BORNSTEIN GADI ,  RAEBER OLIVIA ,  TONGE DAVID WILLIAM ,  YANG XIAO-DONG

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/92

Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described.

Abstract translation: 描述了结合蛋白，例如针对IGF-II的抗体与IGF-1的交叉反应性和这种抗体的用途。

公开(公告)号：WO2008045576A2

公开(公告)日：2008-04-17

申请号：PCT/US2007/021985

申请日：2007-10-12

Applicant: LIU, Yijia ,  LU, Patrick, Y. ,  WOODLE, Martin, C. ,  XIE, Frank, Y. ,  YANG, Xiao, Dong ,  TANG, Quinn

Inventor： LIU, Yijia ,  LU, Patrick, Y. ,  WOODLE, Martin, C. ,  XIE, Frank, Y. ,  YANG, Xiao, Dong ,  TANG, Quinn

IPC: C12N15/11

CPC classification number: C12N15/1136 ,  C12N15/1138 ,  C12N2310/14

Abstract: The invention relates to oligonucleotide compositions for use in reducing the expression and activity of VEGF pathway genes and unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the oligonucleotides.

Abstract translation: 本发明涉及用于通过RNA干扰降低VEGF途径基因的表达和活性以及不期望的新生血管形成（包括肿瘤血管生成）的寡核苷酸组合物，以及包含寡核苷酸的方法和组合物。

公开(公告)号：WO2005012479A2

公开(公告)日：2005-02-10

申请号：PCT/US2004/020564

申请日：2004-06-25

Applicant: ABGENIX, INC ,  WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

Inventor： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC: C12N

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫偶联物。

公开(公告)号：WO2005010151A2

公开(公告)日：2005-02-03

申请号：PCT/US2004020295

申请日：2004-06-25

Applicant: ABGENIX INC ,  WEBER RICHARD ,  FENG XIAO ,  FOORD ORIT ,  GREEN LARRY ,  GUDAS JEAN ,  KEYT BRUCE ,  LIU YING ,  RATHANASWAMI PALANI ,  RAYA ROBERT ,  YANG XIAO DONG ,  CORVALAN JOSE ,  FOLTZ IAN ,  JIA XIAO-CHI ,  KANG JASPAL ,  KING CHADWICK T ,  KLAKAMP SCOTT L ,  SU QIAOJUAN JANE

Inventor： WEBER RICHARD ,  FENG XIAO ,  FOORD ORIT ,  GREEN LARRY ,  GUDAS JEAN ,  KEYT BRUCE ,  LIU YING ,  RATHANASWAMI PALANI ,  RAYA ROBERT ,  YANG XIAO DONG ,  CORVALAN JOSE ,  FOLTZ IAN ,  JIA XIAO-CHI ,  KANG JASPAL ,  KING CHADWICK T ,  KLAKAMP SCOTT L ,  SU QIAOJUAN JANE

IPC: A61K39/395 ,  A61K47/48 ,  C07K16/22 ,  C07K16/28 ,  C07K17/00 ,  C12N20060101 ,  C12N5/06 ,  G01N33/53 ,  C12N

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫缀合物。

公开(公告)号：WO9945031A9

公开(公告)日：1999-11-11

申请号：PCT/US9904583

申请日：1999-03-03

Applicant: ABGENIX INC ,  DAVIS C GEOFFREY ,  BLACHER RUSSELL W ,  CORVALAN JOSE R ,  CULWELL ALAN R ,  GREEN LARRY L ,  HALES JOANNA ,  HAVRILLA NANCY ,  IVANOV VLADIMIR E ,  LIPANI JOHN A ,  LIU QIANG ,  WEBER RICHARD F ,  YANG XIAO DONG

Inventor： DAVIS C GEOFFREY ,  BLACHER RUSSELL W ,  CORVALAN JOSE R ,  CULWELL ALAN R ,  GREEN LARRY L ,  HALES JOANNA ,  HAVRILLA NANCY ,  IVANOV VLADIMIR E ,  LIPANI JOHN A ,  LIU QIANG ,  WEBER RICHARD F ,  YANG XIAO-DONG

IPC: G01N33/53 ,  A61K39/395 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/705 ,  C07K16/28 ,  C12N15/09 ,  C12P21/08 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

Abstract: In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.

Abstract translation: 根据本发明，我们发现在某些细胞如T细胞，B细胞和/或单核细胞上表达的分子CD147可用于治疗各种疾病。 特别是，我们已经证明结合CD147并导致这些细胞例如通过结合补体而杀死这些细胞的抗体在治疗疾病中是有效的。 这种治疗看起来有效的疾病包括但不限于：移植物抗宿主病（GVHD），器官移植排斥疾病（包括但不限于肾移植，眼移植等），癌症（包括但不限于癌症 血液（即白血病和淋巴瘤），胰腺癌等），自身免疫性疾病，炎症性疾病等。

公开(公告)号：WO2008045576A3

公开(公告)日：2009-02-26

申请号：PCT/US2007021985

申请日：2007-10-12

Applicant: LIU YIJIA ,  LU PATRICK Y ,  WOODLE MARTIN C ,  XIE FRANK Y ,  YANG XIAO DONG ,  TANG QUINN

Inventor： LIU YIJIA ,  LU PATRICK Y ,  WOODLE MARTIN C ,  XIE FRANK Y ,  YANG XIAO DONG ,  TANG QUINN

IPC: C12N15/113

CPC classification number: C12N15/1136 ,  C12N15/1138 ,  C12N2310/14

Abstract: The invention relates to oligonucleotide compositions for use in reducing the expression and activity of VEGF pathway genes and unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the oligonucleotides.

Abstract translation: 本发明涉及用于通过RNA干扰降低VEGF途径基因的表达和活性以及不期望的新生血管形成（包括肿瘤血管生成）的寡核苷酸组合物，以及包含寡核苷酸的方法和组合物。

公开(公告)号：WO2006052591A3

公开(公告)日：2006-05-18

申请号：PCT/US2005/039628

申请日：2005-11-02

Applicant: ABGENIX, INC. ,  GAZIT-BORNSTEIN, Gadi ,  SENALDI, Giorgio ,  YANG, Xiao-Dong ,  KEYT, Bruce ,  ZAPATA, Gerardo

Inventor： GAZIT-BORNSTEIN, Gadi ,  SENALDI, Giorgio ,  YANG, Xiao-Dong ,  KEYT, Bruce ,  ZAPATA, Gerardo

IPC: A61K39/395 ,  C12N15/13 ,  C12P21/08

Abstract: The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, n accordance with the present invention, there are provided fully human monoclonal antibodies directed tot he antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR’s), specifically from FR1 through FR4 or CDR1 through CDR3, are provide. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

公开(公告)号：WO03099205A2

公开(公告)日：2003-12-04

申请号：PCT/US0315734

申请日：2003-05-19

Applicant: ABGENIX INC ,  SCHWAB GISELA ,  YANG XIAO-DONG

Inventor： SCHWAB GISELA ,  YANG XIAO-DONG

IPC: C07K16/22 ,  C07K16/28 ,  A61K

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/21

Abstract: Methods of treating renal carcinoma are described using fully human monoclonal antibodies ABX-EGF against the epidermal growth factor receptor (EGFr) and antigen binding fragments thereof. Methods of using these renal carcinoma treatments specifically as a monotherapy are also described. In addition, a kit and an article of manufacture for the treatment of renal carcinoma treatment are provided.

Abstract translation: 使用针对表皮生长因子受体（EGFr）的完全人单克隆抗体ABX-EGF及其抗原结合片段描述治疗肾癌的方法。 还描述了将这些肾癌治疗特异性地用作单一疗法的方法。 另外，提供了用于治疗肾癌治疗的试剂盒和制品。

公开(公告)号：WO9945031A2

公开(公告)日：1999-09-10

申请号：PCT/US9904583

申请日：1999-03-03

Applicant: ABGENIX INC ,  DAVIS C GEOFFREY ,  BLACHER RUSSELL W ,  CORVALAN JOSE R ,  CULWELL ALAN R ,  GREEN LARRY L ,  HALES JOANNA ,  HAVRILLA NANCY ,  IVANOV VLADIMIR E ,  LIPANI JOHN A ,  LIU QIANG ,  WEBER RICHARD F ,  YANG XIAO DONG

Inventor： DAVIS C GEOFFREY ,  BLACHER RUSSELL W ,  CORVALAN JOSE R ,  CULWELL ALAN R ,  GREEN LARRY L ,  HALES JOANNA ,  HAVRILLA NANCY ,  IVANOV VLADIMIR E ,  LIPANI JOHN A ,  LIU QIANG ,  WEBER RICHARD F ,  YANG XIAO-DONG

IPC: G01N33/53 ,  A61K39/395 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/705 ,  C07K16/28 ,  C12N15/09 ,  C12P21/08 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

Abstract: In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.

Abstract translation: 根据本发明，我们发现在诸如T细胞，B细胞和/或单核细胞的某些细胞上表达的分子CD147可用于治疗各种疾病。 特别地，我们已经证明，结合CD147并导致这种细胞的杀伤，例如通过补体结合的抗体在治疗疾病中是有效的。 这种治疗显示有效的疾病包括但不限于：移植物抗宿主病（GVHD），器官移植排斥疾病（包括但不限于肾移植，眼部移植等），癌症（包括但不限于： 血液（即白血病和淋巴瘤），胰腺等），自身免疫疾病，炎性疾病等。

公开(公告)号：WO2007027713A3

公开(公告)日：2007-03-08

申请号：PCT/US2006/033763

申请日：2006-08-28

Applicant: AMGEN INC. ,  GLINIAK, Brian ,  YANG, Xiao-dong ,  WONG-MADDEN, Sharon ,  FOLTZ, Ian ,  FENG, Xiao ,  FITCH, Alison ,  FOSTER, Stephen ,  KETCHEM, Randall, R.

Inventor： GLINIAK, Brian ,  YANG, Xiao-dong ,  WONG-MADDEN, Sharon ,  FOLTZ, Ian ,  FENG, Xiao ,  FITCH, Alison ,  FOSTER, Stephen ,  KETCHEM, Randall, R.

IPC: C07K16/28 ,  C12N15/13 ,  A61K39/00

Abstract: Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand ("TRAIL") Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.